Visão geral da empresa
A biopharmaceutical enterprise, CorMedix Inc., specializes in the development and commercialization of therapeutic products designed to address life-threatening diseases and conditions within the United States market. The company operates within the Healthcare sector and the specific Biotechnology industry, positioning it as an entity focused on innovative medical solutions rather than consumer goods or industrial manufacturing. This organization employs a workforce of 191 individuals and maintains a total market capitalization of $581.81M, while generating annual revenue of $311.71M over the trailing twelve-month period. The substantial market cap relative to its employee count and revenue base suggests a high valuation per unit of labor and sales, indicating that the market prices the company based on future intellectual property potential and clinical trial outcomes rather than current operational cash flows alone. The revenue figure of $311.71M reflects a significant commercialization effort, though the scale must be viewed in the context of a pre-commercial or early-commercial stage biotechnology firm where revenue drivers are often tied to specific product launches like DefenCath.
Saúde financeira
CorMedix Inc. reported a revenue of $311.71M, net income of $162.07M, and EBITDA of $174.89M for the trailing twelve months, highlighting a distinct disparity between top-line sales and bottom-line profitability. The gap between the $311.71M revenue and $162.07M net income reveals a highly efficient cost structure where operating expenses and cost of goods sold consume only a fraction of total sales, a characteristic often seen in successful biotechnology transitions from research to commercialization. The company generated free cash flow of $108.51M, which provides significant financial flexibility to fund ongoing research and development programs without relying heavily on external equity financing. When analyzing profitability margins, the gross margin stands at 92.9%, indicating that the cost to manufacture the therapeutic products is negligible compared to sales; the operating margin is 53.9%, showing strong control over operating expenditures; and the profit margin reaches 52.3%, demonstrating that more than half of every dollar of revenue translates directly to net profit. Regarding leverage, the company holds $148.53M in cash against $148.91M in debt, resulting in a debt-to-equity ratio of 36.74, which implies a balance sheet that is effectively neutral with cash almost entirely offsetting debt obligations. The current ratio of 2.11 indicates robust short-term liquidity, suggesting the company possesses ample current assets to cover its current liabilities with a comfortable safety margin. Furthermore, the return on equity is 66.6% and the return on assets is 21.2%, metrics that reveal exceptional management effectiveness in deploying shareholder capital and generating returns on the total asset base utilized for operations.
Avaliação de valorização
The valuation metrics show a trailing P/E ratio of 3.61 and a forward P/E of 10.08, where the difference implies that the market expects earnings to recover or expand significantly in the coming years to justify the higher multiple. The price-to-book ratio is 1.44, which indicates a moderate market premium over the company's book value, suggesting that investors are willing to pay approximately 44% above the net asset value for the company's growth prospects and intangible assets. Alternative valuation metrics include a price-to-sales ratio of 1.87 and an EV/EBITDA of 3.33, which suggest that the company is trading at a reasonable multiple relative to its sales volume and earnings power, despite the low trailing earnings yield. The 52-week price range spans from a low of $6.13 to a high of $17.43, and assuming the current market price aligns with the trailing P/E of 3.61 applied to the earnings, the stock is trading within a specific band relative to this historical range, reflecting recent market volatility. The beta value is 1.41, which means the stock's price volatility is 41% higher than that of the broader market, indicating that CorMedix tends to amplify market movements during periods of systemic risk or opportunity.
Growth & Income
The company experienced a revenue growth of 312.1% year-over-year, while earnings growth was -28.3%, indicating that earnings are currently growing slower than revenue, likely due to non-recurring costs or one-time adjustments affecting the net income calculation in the current period. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which explains that the entity reinvests all generated earnings back into its core business operations, clinical trials, and product development rather than distributing cash to shareholders. This strategy of zero dividends combined with massive revenue growth suggests the management team prioritizes capital allocation toward scaling the DefenCath product and advancing other therapeutic candidates over immediate shareholder returns. The overall growth and income profile is characterized by explosive top-line expansion and retained earnings, presenting a high-risk, high-reward scenario typical of biotechnology firms that have recently achieved commercial milestones but have yet to stabilize earnings growth to match revenue acceleration.